Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Targeted therapies, including biologic DMARDs and Janus kinase inhibitors, can interfere with the mechanisms of pathological bone metabolism in inflammatory arthritis. In this Review, the authors discuss the effects of these therapies on local and generalized bone changes.
Undifferentiated arthritis (UA) was redefined by the introduction of the 2010 rheumatoid arthritis (RA) classification criteria. But UA is more than just not having RA — it is about selecting the right patients for DMARD treatment even before diagnosis, and about protecting those with self-limiting disease from potential drug toxicity.
In this Review, the authors summarize the current knowledge relating to SARS-CoV-2 infection and the prevention and treatment of COVID-19 in people with rheumatic disease.
The COVID-19 pandemic has caused a rapid transition towards telemedicine, raising concerns about assessment accuracy, medical-relationship building and potential inequalities between patient groups. For some rheumatology patients, telemedicine is convenient and acceptable, but careful selection and choice are important.
This Review examines the biology of synovial inflammation, the cell types involved, their interactions and the role of synovitis in the development and progression of osteoarthritis.
Erosive hand osteoarthritis is an aggressive condition with poor outcomes. In this Review, the authors describe the clinical features and risk factors associated with erosive hand osteoarthritis, and summarize progress in the areas of biomarkers, imaging, classification criteria and treatment.
Here, the authors describe the mechanisms that normally limit function and survival of activated T cells in peripheral tissues and discuss how defects in these processes can facilitate the development of chronic inflammatory responses that underlie organ damage in rheumatic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.
In this Review, Paggi et al. discuss the requirements and challenges in engineering a joint-on-chip device, propose an architecture for such a model of the joint and highlight the potential for these platforms to further advance insight into arthritic diseases and facilitate drug development.
This Review discusses progress in identifying potential outcome measures and developing treatment options to achieve a treat-to-target approach in systemic lupus erythematosus, as well as the research advances that are needed to realize these objectives.
Several rheumatic diseases are associated with an increased risk of cardiovascular disease. In this Review, the authors outline the role of neutrophils in rheumatic disease pathogenesis and in vascular inflammation, and draw parallels with cardiovascular disease.
The COVID-19 pandemic has put pressure on researchers around the world. In this Viewpoint, six rheumatology researchers at different career stages and from different regions discuss the difficulty of conducting research during the pandemic, and also reflect on how the pandemic has changed their attitudes towards research and their plans for the future.
Janus kinase inhibition modulates a range of immune and inflammatory processes. In this Review, the authors discuss progress in the therapeutic use of Janus kinase inhibitors in autoimmune rheumatic diseases, with a focus on their disease-specific mechanisms of action.
